Market Cap 4.71B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 40.09
Forward PE 45.35
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 500,000
Avg Vol 1,637,768
Day's Range N/A - N/A
Shares Out 169.18M
Stochastic %K 75%
Beta 0.67
Analysts Strong Sell
Price Target $28.95

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 212 0513
Address:
12830 El Camino Real, Suite 400, San Diego, United States
Doozio
Doozio Dec. 24 at 12:02 AM
$ACAD bahht they wull EXEL because only da 🐑 will be shook ENTA 🐒🍌🧠⏰♾️. New all timers barrring a faatch 💣 in 2026
0 · Reply
StockConsultant
StockConsultant Dec. 22 at 3:51 PM
$ACAD Acadia Pharmaceuticals stock with a bull flag breakout
0 · Reply
dgbio
dgbio Dec. 20 at 3:06 AM
$ACAD 'Real-world use of trofinetide: a survey of practices from prescribers: • Most respondents (95%, n = 21) indicated they titrate trofinetide and 86% (n = 19) believed titration improved tolerability. • Respondents estimated a median 75% of patients achieve their label dose after titration. • Respondents encourage families to remain on trofinetide for a median of ≥16 weeks to adequately evaluate efficacy; most (77%, n = 17) indicated this period should start after the patient arrives at their highest tolerable dose'. https://www.tandfonline.com/doi/full/10.1080/23995270.2025.2597031?src=#abstract
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:20 PM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $26.6, nearing its 60D high of $27.73. The RSI at 64.72 indicates bullish momentum but is approaching overbought territory. The stock is above its 30-day moving average (MA30) of $24.98 and 50-day moving average (MA50) of $23.63, suggesting a strong upward trend. Directional Bias: Given the current price action and the proximity to the 60D high, there is a bullish bias. The price is well-supported above the MAs, indicating potential for further gains. Trade Plan: - Suggested Entry: $26.6 - Stop Loss: $24.5 (approximately 7% below entry) - Take Profit Targets: 1. $28.00 (5.3% gain) 2. $29.50 (10.4% gain) 3. $31.20 (17.3% gain) This plan allows for a risk-reward ratio that meets the 17% ROI target on the third take profit. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 19 at 4:08 PM
0 · Reply
zeustony88
zeustony88 Dec. 19 at 2:51 PM
$ACAD $28 today?
1 · Reply
JFDI
JFDI Dec. 19 at 2:00 PM
$ACAD 3wt at high end range
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 18 at 11:08 AM
0 · Reply
SBL71
SBL71 Dec. 17 at 5:32 PM
0 · Reply
Quantumup
Quantumup Dec. 17 at 1:45 PM
Citizens $TSHA Market Outperform/$8 $NGNE $NVS $ACAD AVXL $ALPMY Citizens said—Taysha (TSHA, MO, $8 PT) and Neurogene (NGNE, NC) are moving into registrational studies and both show significant promise. Both registrational studies are well-designed, according to Dr. Davies, to capture improvements in clinical benefit and leverage primary outcomes that are objective measurements of performance outcomes and not patient/caregiver reported or effort based, which are less meaningful.
0 · Reply
Latest News on ACAD
Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 5 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In


These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 7 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals


Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 7 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview


ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 8 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts


Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 10 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing


Doozio
Doozio Dec. 24 at 12:02 AM
$ACAD bahht they wull EXEL because only da 🐑 will be shook ENTA 🐒🍌🧠⏰♾️. New all timers barrring a faatch 💣 in 2026
0 · Reply
StockConsultant
StockConsultant Dec. 22 at 3:51 PM
$ACAD Acadia Pharmaceuticals stock with a bull flag breakout
0 · Reply
dgbio
dgbio Dec. 20 at 3:06 AM
$ACAD 'Real-world use of trofinetide: a survey of practices from prescribers: • Most respondents (95%, n = 21) indicated they titrate trofinetide and 86% (n = 19) believed titration improved tolerability. • Respondents estimated a median 75% of patients achieve their label dose after titration. • Respondents encourage families to remain on trofinetide for a median of ≥16 weeks to adequately evaluate efficacy; most (77%, n = 17) indicated this period should start after the patient arrives at their highest tolerable dose'. https://www.tandfonline.com/doi/full/10.1080/23995270.2025.2597031?src=#abstract
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:20 PM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $26.6, nearing its 60D high of $27.73. The RSI at 64.72 indicates bullish momentum but is approaching overbought territory. The stock is above its 30-day moving average (MA30) of $24.98 and 50-day moving average (MA50) of $23.63, suggesting a strong upward trend. Directional Bias: Given the current price action and the proximity to the 60D high, there is a bullish bias. The price is well-supported above the MAs, indicating potential for further gains. Trade Plan: - Suggested Entry: $26.6 - Stop Loss: $24.5 (approximately 7% below entry) - Take Profit Targets: 1. $28.00 (5.3% gain) 2. $29.50 (10.4% gain) 3. $31.20 (17.3% gain) This plan allows for a risk-reward ratio that meets the 17% ROI target on the third take profit. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 19 at 4:08 PM
0 · Reply
zeustony88
zeustony88 Dec. 19 at 2:51 PM
$ACAD $28 today?
1 · Reply
JFDI
JFDI Dec. 19 at 2:00 PM
$ACAD 3wt at high end range
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 18 at 11:08 AM
0 · Reply
SBL71
SBL71 Dec. 17 at 5:32 PM
0 · Reply
Quantumup
Quantumup Dec. 17 at 1:45 PM
Citizens $TSHA Market Outperform/$8 $NGNE $NVS $ACAD AVXL $ALPMY Citizens said—Taysha (TSHA, MO, $8 PT) and Neurogene (NGNE, NC) are moving into registrational studies and both show significant promise. Both registrational studies are well-designed, according to Dr. Davies, to capture improvements in clinical benefit and leverage primary outcomes that are objective measurements of performance outcomes and not patient/caregiver reported or effort based, which are less meaningful.
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 17 at 12:23 PM
$ACAD Braidwell just picked up 2.78 million shares on 11-14 and Frazier picked up 613 K shares. What do they know that we do not? BTW, I sold my shares years ago right before the steep decline thanks to the FAKE FDA! Is this still considered a BO Canidate?
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:06 AM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $26.8, close to its 60-day high of $27.73. The RSI at 71.95 indicates an overbought condition, suggesting a potential pullback. However, the proximity to the high and the positive sentiment could still offer short-term trading opportunities. Directional Bias: Given the RSI is above 70, we anticipate a possible retracement. The moving averages (MA30 at 24.67 and MA50 at 23.41) indicate a bullish trend, but the current price action suggests caution. Trade Plan: - Suggested Entry: $26.5 - Stop Loss: $25.5 (1.3% risk) - Take Profit Targets: 1. $27.0 (1.9% gain) 2. $27.5 (3.8% gain) 3. $31.5 (17.3% gain) This plan allows for a risk-reward ratio that aligns with a potential 17% ROI on the third target. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 4:00 PM
HC Wainwright & Co. has updated their rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy with a price target of 37.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:38 AM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $27.15, showing strength with an RSI of 81.22, indicating it is overbought. The stock is above its 30-day MA of $24.37 and 50-day MA of $23.20, suggesting bullish momentum. However, the high of $27.73 in the last 60 days presents a resistance level to watch. Directional Bias: The strong RSI signals potential for a pullback, but the stock's position above key moving averages indicates a bullish trend. The 60-day low of $19.69 offers a solid support base. Trade Plan: - Entry: $27.15 - Stop Loss: $25.50 (approx. 6.1% risk) - Take Profit Targets: 1. $28.00 (3.1% gain) 2. $29.00 (6.8% gain) 3. $31.85 (17.7% gain) This plan aims for a minimum ROI of 17% on the third target while keeping risk manageable. Monitor price action closely around the targets and adjust as necessary. https://privateprofiteers.com
0 · Reply
SBL71
SBL71 Dec. 12 at 2:22 PM
$ACAD will be see a $30 new year??
0 · Reply
copywrites
copywrites Dec. 12 at 1:18 PM
$ACAD 👀👍🏽
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:32 AM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $26.72, with a strong RSI of 82.37 indicating overbought conditions. However, the stock has shown resilience, trading above its 30-day moving average (MA30) of 24.23 and 50-day moving average (MA50) of 23.08, suggesting bullish momentum. Directional Bias: The recent price action near the 60-day high of $27.73 indicates potential for further gains, despite the overbought RSI. The low of $19.69 provides a solid reference for risk management. Trade Plan: - Suggested Entry: $26.72 - Stop Loss: $25.00 (approx. 6.4% risk) - Take Profit Targets: 1. $28.00 (5% gain) 2. $30.00 (12% gain) 3. $31.25 (17% gain) This trade offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the price action closely and adjust stops as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 1:15 PM
Stifel has adjusted their stance on ACADIA Pharmaceuticals ( $ACAD ), setting the rating to Hold with a target price of 24 → 25.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 1:19 PM
$ACAD Current Stock Price: $26.89 Contracts to trade: $25 ACAD Dec 19 2025 Call Entry: $1.83 Exit: $2.56 ROI: 40% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:35 AM
Actionable Trade Alert for $ACAD: Market Context: $ACAD is currently trading at $26.89, showing strong momentum with an RSI of 73.3, indicating overbought conditions. The stock is above its 30-day MA of $23.95 and 50-day MA of $22.87, suggesting bullish sentiment. However, the high of $27.73 in the last 60 days presents a resistance level that could limit upside potential. Directional Bias: Given the high RSI, there may be a pullback, but the overall trend remains bullish due to the stock's position above key moving averages. The range between the 60D high ($27.73) and low ($19.69) supports potential upward movement. Trade Plan: - Suggested Entry: $26.50 - Stop Loss: $25.00 (risking $1.50) - Take Profit Targets: 1. $28.00 (Target 1: 5.7% ROI) 2. $29.00 (Target 2: 9.9% ROI) 3. $31.50 (Target 3: 17.7% ROI) Monitor for volatility with an ATR of $0.92. Adjust positions accordingly. https://privateprofiteers.com
0 · Reply
RichieMagaoneCarter
RichieMagaoneCarter Dec. 9 at 4:39 PM
Oh wow my $ACAD has now double so I will take some profits ! Thank You
0 · Reply
zeustony88
zeustony88 Dec. 9 at 4:00 PM
$ACAD Now all we need is a crazy buyout rumor.
1 · Reply